| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences, Inc. (GILD) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. GILD is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 626.3K | $79.13M | -15,000 | |
| Other | 46.9K | $5.93M | - | |
| Other | 46.6K | $5.89M | - | |
| VP | 44.2K | $5.58M | - | |
| Other | 27.9K | $3.52M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 27, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $79.90 | $192,798.70 | -4.2% | |
| Apr 20, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $83.00 | $200,279.00 | -4.2% | |
| Apr 13, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $75.90 | $183,146.70 | -4.2% | |
| Apr 6, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $79.52 | $191,881.76 | -4.2% | |
| Mar 30, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $75.35 | $181,819.55 | -4.2% | |
| Mar 23, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $75.27 | $181,626.51 | -4.2% | |
| Mar 16, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $67.26 | $162,298.38 | -4.2% | |
| Mar 10, 2020 | Pletcher Brett A | EVP,Corp Affairs &Gen Counsel | Sale+OE | 2,950 | $75.55 | $222,872.50 | -16.8% | |
| Mar 9, 2020 | Cogan John Francis | Director | Sale+OE | 2,413 | $77.97 | $188,141.61 | -4.2% | |
| Mar 2, 2020 | Pletcher Brett A | EVP,Corp Affairs &Gen Counsel | Sell | 10,441 | $70.88 | $740,013.53 | -25.6% |